Bioventus Inc. (BVS) Key Metrics
BVS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $908.5M
- Enterprise value
- $1.15B
- P/E (TTM)
- 17.1
- Forward P/E
- 14.8
- PEG ratio
- 1.53
- Price / sales
- 1.6 10-yr median 0.9
- Price / book
- 4.1 10-yr median 1.9
- EV / EBITDA
- 11.1 10-yr median 21.4
- Dividend yield
- —
- Beta
- 0.64
BVS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBVS valuation Price multiples at each fiscal year-end price.
BVS returns How much profit the business earns on the capital it uses.
BVS per-share figures Results divided by the shares outstanding at year-end.
BVS financial health Debt, liquidity and how easily interest is covered.
BVS efficiency & capital use Working capital cycle and where the cash goes.
BVS valuation history
BVS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BVS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BVS cash returned to shareholders
BVS price vs earnings per share
BVS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $512.7M | $686.2M | $330.2M | $160.2M | $658.9M | — | — | — | — | — |
| Enterprise value | $772.8M | $980.3M | $688.0M | $548.1M | $972.6M | — | — | — | — | — |
| P/E ratio | 22.6 | — | — | — | 34.0 | — | — | — | — | — |
| Price / sales | 0.9 | 1.2 | 0.6 | 0.3 | 1.5 | — | — | — | — | — |
| Price / book | 2.8 | 4.6 | 1.9 | 0.5 | 1.4 | — | — | — | — | — |
| Price / free cash flow | 7.2 | 18.2 | 41.4 | — | 42.2 | — | — | — | — | — |
| Price / operating cash flow | 6.9 | 17.7 | 21.5 | — | 28.7 | — | — | — | — | — |
| EV / sales | 1.4 | 1.7 | 1.3 | 1.1 | 2.3 | — | — | — | — | — |
| EV / EBITDA | 7.8 | 25.0 | — | — | 21.4 | — | — | — | — | — |
| EV / free cash flow | 10.8 | 25.9 | 86.2 | — | 62.3 | — | — | — | — | — |
| Earnings yield | 4.4% | −4.9% | −47.3% | −99.1% | 2.9% | — | — | — | — | — |
| Free cash flow yield | 13.9% | 5.5% | 2.4% | −9.4% | 2.4% | — | — | — | — | — |
| Dividend yield | — | — | — | 5.7% | 0.1% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 7.8% | 0.1% | — | — | — | — | — |
| Share price at fiscal year-end | $7.44 | $10.50 | $5.27 | $2.61 | $14.49 | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $8.24 | $8.77 | $8.18 | $8.34 | $9.48 | $8.52 | $5.99 | $5.62 | $5.14 | $4.83 |
| Earnings per share | $0.33 | −$0.51 | −$2.49 | −$2.59 | $0.43 | $0.44 | $0.12 | −$0.21 | −$0.03 | −$0.32 |
| Operating cash flow per share | $1.07 | $0.59 | $0.24 | −$0.22 | $0.51 | $1.90 | $0.72 | $0.80 | — | — |
| Free cash flow per share | $1.04 | $0.58 | $0.13 | −$0.24 | $0.34 | $1.36 | $0.57 | $0.69 | — | — |
| Cash per share | $0.74 | $0.64 | $0.59 | $0.49 | $0.97 | $2.30 | $1.14 | $0.75 | — | — |
| Book value per share | $2.67 | $2.26 | $2.77 | $5.30 | $10.09 | $3.77 | $2.52 | $2.56 | — | — |
| Tangible book value per share | −$2.78 | −$4.04 | −$5.05 | −$5.25 | −$8.44 | −$2.63 | −$2.17 | −$2.49 | — | — |
| Dividends per share | — | — | — | $0.15 | $0.01 | $0.53 | $0.16 | $0.14 | — | — |
| Capex per share | $0.04 | $0.02 | $0.12 | $0.02 | $0.16 | $0.55 | $0.15 | $0.11 | — | — |
| Debt per share | $4.52 | $5.14 | $6.30 | $6.81 | $7.87 | $5.00 | $3.48 | $3.43 | — | — |
| Shares outstanding | 68.9M | 65.4M | 62.6M | 61.4M | 45.5M | 37.7M | 56.8M | 56.8M | 56.8M | 56.8M |
| Change in shares outstanding | +5.4% | +4.3% | +2.0% | +35.0% | +20.6% | −33.7% | 0.0% | 0.0% | 0.0% | +2.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 13.7% | −20.9% | −62.6% | −40.5% | 6.4% | 11.5% | 4.8% | −8.4% | — | — |
| Return on invested capital (ROIC) | 13.2% | −1.9% | −10.4% | −17.8% | 2.4% | 7.6% | 9.1% | 6.2% | — | — |
| Return on assets (ROA) | 3.2% | −4.4% | −14.3% | −12.2% | 2.3% | 3.4% | 1.5% | −2.8% | — | — |
| Return on tangible assets | 7.4% | −10.6% | −48.7% | −21.9% | 5.1% | 6.5% | 3.3% | −7.8% | — | — |
| Free cash flow margin | 12.6% | 6.6% | 1.6% | −2.9% | 3.6% | 15.9% | 9.5% | 12.3% | — | — |
| Income quality (OCF / net income) | 3.25 | — | — | — | 1.19 | 4.38 | 5.94 | — | — | — |
| Financial health | ||||||||||
| Total debt | $311.3M | $335.6M | $394.8M | $418.1M | $357.7M | $188.4M | $198.0M | $194.8M | — | — |
| Cash & short-term investments | $51.2M | $41.6M | $37.0M | $30.2M | $43.9M | $86.8M | $64.5M | $42.8M | — | — |
| Net debt | $260.1M | $294.0M | $357.9M | $387.9M | $313.7M | $101.5M | $133.4M | $152.1M | — | — |
| Debt / equity | 1.69 | 2.27 | 2.27 | 1.29 | 0.78 | 1.32 | 1.38 | 1.34 | — | — |
| Debt / assets | 0.46 | 0.46 | 0.49 | 0.30 | 0.29 | 0.38 | 0.42 | 0.44 | — | — |
| Net debt / EBITDA | 2.62 | 7.50 | — | — | 6.90 | 1.87 | 2.17 | 2.79 | — | — |
| Current ratio | 1.70 | 1.31 | 1.53 | 0.90 | 1.45 | 1.73 | 2.06 | 2.27 | — | — |
| Quick ratio | 1.19 | 0.87 | 1.01 | 0.62 | 1.11 | 1.49 | 1.75 | 1.85 | — | — |
| Interest coverage | 2.2 | -0.3 | -2.0 | -13.9 | 10.8 | 2.2 | 1.4 | 1.3 | 1.4 | 0.9 |
| Working capital | $112.5M | $65.2M | $92.5M | −$31.4M | $82.2M | $89.2M | $94.0M | $82.9M | — | — |
| Invested capital | $444.2M | $442.0M | $531.5M | $713.1M | $772.7M | $243.8M | $276.4M | $297.3M | — | — |
| Tangible asset value | −$147.4M | −$226.6M | −$268.7M | −$235.1M | −$309.0M | −$97.3M | −$120.7M | −$141.6M | — | — |
| Net current asset value | −$182.3M | −$266.7M | −$321.8M | −$687.9M | −$429.0M | −$138.5M | −$143.8M | −$149.1M | — | — |
| Graham number | $4.45 | — | — | — | $9.84 | $6.08 | $2.61 | — | — | — |
| Graham net-net per share | −$3.87 | −$5.49 | −$6.63 | −$12.80 | −$11.51 | −$4.85 | −$3.25 | −$3.28 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $9.1M | $367,000 | $19.9M | $9.1M | $7.8M | — | — |
| Share buybacks (net) | — | — | — | $3.4M | $0 | — | — | — | — | — |
| Dividend payout ratio | — | — | — | — | 1.9% | 121.2% | 133.4% | — | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | 2.3% | 38.9% | 28.2% | 20.1% | — | — |
| Capex / revenue | 0.5% | 0.2% | 1.4% | 0.3% | 1.7% | 6.4% | 2.5% | 1.9% | — | — |
| Capex / operating cash flow | 3.5% | 2.6% | 48.0% | — | 32.1% | 28.8% | 20.5% | 13.4% | — | — |
| Capex / depreciation | 0.05 | 0.02 | 0.13 | 0.03 | 0.21 | 0.72 | 0.28 | 0.21 | — | — |
| Stock-based compensation / revenue | 2.2% | 1.8% | 0.5% | 3.4% | −1.0% | 3.1% | 3.2% | 4.5% | — | — |
| R&D / revenue | 2.1% | 2.4% | 2.6% | 4.7% | 4.4% | 3.5% | 3.3% | 2.5% | 2.8% | 2.9% |
| SG&A / revenue | 55.3% | 57.1% | 59.3% | 64.9% | 59.0% | 60.1% | 58.4% | 60.1% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 82.1 | 79.6 | 92.3 | 93.1 | 90.3 | 98.5 | 84.9 | 83.5 | — | — |
| Days of inventory on hand | 171.7 | 181.3 | 174.5 | 147.6 | 129.3 | 117.5 | 109.8 | 118.8 | — | — |
| Days payables outstanding | 34.0 | 46.1 | 59.2 | 54.0 | 30.4 | 22.6 | 29.4 | 35.6 | — | — |
| Cash conversion cycle (days) | 219.9 | 214.8 | 207.6 | 186.7 | 189.2 | 193.5 | 165.3 | 166.7 | — | — |
| Receivables turnover | 4.44 | 4.58 | 3.96 | 3.92 | 4.04 | 3.70 | 4.30 | 4.37 | — | — |
| Payables turnover | 10.73 | 7.92 | 6.17 | 6.75 | 12.02 | 16.14 | 12.42 | 10.26 | — | — |
| Inventory turnover | 2.13 | 2.01 | 2.09 | 2.47 | 2.82 | 3.11 | 3.32 | 3.07 | — | — |
| Asset turnover | 0.80 | 0.75 | 0.47 | 0.39 | 0.50 | 0.66 | 0.74 | 0.72 | — | — |
| Average receivables | $127.8M | $125.1M | $129.5M | $130.6M | $106.6M | $86.7M | $79.1M | $73.0M | — | — |
| Average payables | $17.3M | $23.4M | $29.9M | $26.8M | $10.7M | $5.4M | $7.3M | $8.2M | — | — |
| Average inventory | $87.4M | $91.9M | $88.0M | $73.2M | $45.4M | $28.2M | $27.4M | $27.4M | — | — |
| Intangibles / total assets | 55.0% | 56.6% | 60.4% | 47.2% | 68.8% | 48.8% | 56.4% | 64.8% | — | — |
Computed from BVS's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BVS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Bioventus traded at 22.6 times earnings. Based on the latest twelve months, the trailing P/E is 17.1 and the forward P/E is 14.8. Bioventus earned a return on equity of 13.7% and a return on invested capital of 13.2% in fiscal 2025. It ended the year with $311.3 million of debt and $51.2 million in cash and short-term investments, net debt of $260.1 million. The share count rose 21.3% from 56.8M to 68.9M over 9 years.
See the BVS income statement, the BVS chart for price history, or the BVS stock overview for the latest quote and news.
BVS key metrics FAQ
What is Bioventus's P/E ratio?
Bioventus's trailing P/E ratio is 17.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 14.8. At the end of fiscal 2025 it was 22.6.
What is Bioventus's EV/EBITDA?
Bioventus's enterprise value was 7.8 times EBITDA at the end of fiscal 2025 (enterprise value $772.8 million, EBITDA $99.2 million); the current EV/EBITDA is 11.1.
What is Bioventus's return on equity?
Bioventus's return on equity (ROE) was 13.7% in fiscal 2025: net income of $22.7 million on average shareholders' equity of $166.0 million.
What is Bioventus's ROIC?
Bioventus's return on invested capital was 13.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Bioventus have?
Bioventus had total debt of $311.3 million at the end of fiscal 2025, a debt-to-equity ratio of 1.69 and $260.1 million of net debt (2.62 times EBITDA).
What is Bioventus's free cash flow yield?
Bioventus generated $71.4 million of free cash flow in fiscal 2025, a free cash flow yield of 13.9% on its market value at year-end ($512.7 million).
What is Bioventus's current ratio?
Bioventus's current ratio was 1.70 at the end of fiscal 2025: current assets were 1.70 times current liabilities.